InsiderSource

HOMCY CHARLES J

Director, Chairman of Pharmaceuticals · SEC CIK 1192591
Insider at MAZE Maze Therapeutics, Inc. BBIO BridgeBio Pharma, Inc. PLRX PLIANT THERAPEUTICS, INC. PHIC Population Health Investment Co., Inc. PTLA PORTOLA PHARMACEUTICALS INC GBT Global Blood Therapeutics, Inc.
Advertisement

Buy track record

How this insider's open-market purchases have performed
This insider has no open-market purchases in the records we parsed, so there's no buy track record to score. Their full filing history is below.
Advertisement
Open-market buys
$0
0 trades
Open-market sells
$20.65M
12 trades
Net flow
−$20.65M
Net selling
Total filings
45
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Oct 1, 2020 ΔOwn −0.8%

Homcy Charles J sold $380K of BBIO, trimming their stake 1%.

−$380K
10,000 sh @ $38
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Sep 29, 2020 ΔOwn −1.5%

Homcy Charles J sold $682.5K of BBIO, trimming their stake 1%.

−$682.5K
18,200 sh @ $38
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Sep 29, 2020 ΔOwn −5.0%

Homcy Charles J sold $2.41M of BBIO, trimming their stake 5%.

−$2.41M
65,661 sh @ $37
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Sep 29, 2020 ΔOwn −1.2%

Homcy Charles J sold $576.9K of BBIO, trimming their stake 1%.

−$576.9K
15,396 sh @ $37
Advertisement
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Feb 12, 2020 ΔOwn −1.5%

Homcy Charles J sold $720K of BBIO, trimming their stake 1%.

−$720K
20,000 sh @ $36
BBIO
BridgeBio Pharma, Inc.
Sell HOMCY CHARLES J · Director, Chairman of Pharmaceuticals · Open-market sale · filed Jan 16, 2020 ΔOwn −0.7%

Homcy Charles J sold $350K of BBIO, trimming their stake 1%.

−$350K
10,000 sh @ $35
PTLA
PORTOLA PHARMACEUTICALS INC
Sell HOMCY CHARLES J · Director · Open-market sale · filed Dec 19, 2018 ΔOwn −36%

Homcy Charles J sold $1.18M of PTLA, trimming their stake 36%.

−$1.18M
63,518 sh @ $19

Frequently asked questions

How is HOMCY CHARLES J's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from HOMCY CHARLES J's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.